Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
30 participants
OBSERVATIONAL
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The use of CTC has been investigated and shown to predict progression free survival and overall survival in metastatic breast cancer, and recommended as a breast cancer tumor marker by the American Society of Clinical Oncology. There have also been relationships between CTC's and survival, shown in metastatic colorectal and prostate cancer. However, CTC's have not been thoroughly investigated in non-small cell lung cancer. This trial will assess if the detection of circulating tumor cells could be used as a tool to help further advance treatment for NSCLC patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years of age and older
* Diagnosis of new or recurrent non-small cell lung cancer
* Awaiting treatment and follow up
* Have radiographic measurable metastatic disease that can be followed
* Be able to sign an IRB approved informed consent form
* Life expectancy greater than 12 weeks
For subjects with COPD and without lung malignancies:
* 18 years of age and older
* Diagnosis of COPD
* No current or prior malignancies (except squamous or basal cell carcinoma of the skin)
* Be able to sign an IRB approved informed consent form
For Healthy Control Subjects (Dry Runs):
* 18 years of age and older
* Has no current or prior malignancies (except squamous or basal cell carcinoma of the skin)
* Patients must sign an IRB approved informed consent form
Exclusion Criteria
* Have other concurrent lung cancer malignancies, or any other form of malignancy (except squamous or basal cell carcinoma of the skin)
* ECOG performance status of 4
* Pregnant female (self-reporting)
* Cognitively Impaired
* Prisoner
For subjects with COPD and without lung malignancies and Healthy Controls:
* Any other form of malignancy (except squamous or basal cell carcinoma of the skin)
* Pregnant female (self reporting)
* Cognitively impaired
* Prisoner
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Virginia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thao Dang, MD
Role: PRINCIPAL_INVESTIGATOR
University of Virginia Health System
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Virginia Health System
Charlottesville, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Royanne Dell
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15847
Identifier Type: -
Identifier Source: org_study_id